do we or do we not lose exclusive rights to the hemangioblast program ?
how much research money has been put toward meeting our 6.75 million obligation?
what will be the consequences of a not meeting this obligation?
why don't they report what has been on this particular research it should not be lumped together as just research.
should we expect a scientific publishing of on platelets? will they file an IND before JUly 2014
and do you even care?
I do care and great questions....
However let me smoke peace pipe and conjour the Huffingting Post....The I will copy and paste the answer for you.....Cause it is all true....More so than the Internet.....Trust....
Sentiment: Strong Buy
lastbull, operating expenses on research and development were for:
It looks to me like expenses that are or could be listed under Hemangioblast research and development will certainly by 2014 (if not already done) easily eclipse $6.7 M.
i hope you are right but it would seem prudent to break it down for investers .....so we know
and the term sheet was entered into in July of 2011 so anything before that is irrelevant
also lets say CHA wanted to buy out our 40% what would you take
We will lose licensing rights to hemo in US and Canada-I would not sell out to CHA. Agreement terminates at end of last license. Don't we have hostages in the lab? Platelets probably need six-nine more months.